Introducing LucidBio Intelligence
Get Strategic Clarity Before Your Next Milestone
We deliver analyst-driven competitive intelligence that helps biotech teams make smarter decisions—from trial design and fundraising to regulatory positioning. Fast delivery. Clear insights. No enterprise platform overhead.
Introducing LucidBio Intelligence
Get Strategic Clarity Before Your Next Milestone
We deliver analyst-driven competitive intelligence that helps biotech teams make smarter decisions—from trial design and fundraising to regulatory positioning. Fast delivery. Clear insights. No enterprise platform overhead.
Introducing LucidBio Intelligence
Get Strategic Clarity Before Your Next Milestone
We deliver analyst-driven competitive intelligence that helps biotech teams make smarter decisions—from trial design and fundraising to regulatory positioning. Fast delivery. Clear insights. No enterprise platform overhead.
AI in Pharmaceutical Safety Competitive Intelligence Report
AI in Pharmaceutical Safety Competitive Intelligence Report
See how 12+ companies are positioning AI in drug safety and compliance—regulatory strategies, market opportunities, and competitive analysis.
See how 12+ companies are positioning AI in drug safety and compliance—regulatory strategies, market opportunities, and competitive analysis.
LucidBio Advisory Services
Who We Serve
LucidBio Advisory Services
Who We Serve
LucidBio Advisory Services
Who We Serve
Pre-Series B companies preparing for fundraising who need to demonstrate competitive differentiation to investors.
→ Competitive positioning analysis
→ Trial design intelligence
→ Regulatory pathway mapping
Pre-Series B companies preparing for fundraising who need to demonstrate competitive differentiation to investors.
→ Competitive positioning analysis
→ Trial design intelligence
→ Regulatory pathway mapping
Pre-Series B companies preparing for fundraising who need to demonstrate competitive differentiation to investors.
→ Competitive positioning analysis
→ Trial design intelligence
→ Regulatory pathway mapping
Clinical Development Leaders
VPs and directors designing trials who need to understand how competitors are approaching endpoints, populations, and study designs.
→ Competitor trial analysis
→ Endpoint strategy intelligence
→ Patient population benchmarking
Clinical Development Leaders
VPs and directors designing trials who need to understand how competitors are approaching endpoints, populations, and study designs.
→ Competitor trial analysis
→ Endpoint strategy intelligence
→ Patient population benchmarking
Clinical Development Leaders
VPs and directors designing trials who need to understand how competitors are approaching endpoints, populations, and study designs.
→ Competitor trial analysis
→ Endpoint strategy intelligence
→ Patient population benchmarking
Heads of strategy assessing partnership opportunities, licensing deals, or market entry decisions with competitive context.
→ Market landscape analysis
→ Deal intelligence
→ Competitive positioning
Heads of strategy assessing partnership opportunities, licensing deals, or market entry decisions with competitive context.
→ Market landscape analysis
→ Deal intelligence
→ Competitive positioning
Heads of strategy assessing partnership opportunities, licensing deals, or market entry decisions with competitive context.
→ Market landscape analysis
→ Deal intelligence
→ Competitive positioning
How We Work With You
How We Work With You
How We Work With You
Competitive Intelligence Reports
For Specific Milestones & Decisions
Get a focused competitive landscape report in 2 weeks covering your key competitors, their strategies, and positioning recommendations. Perfect for: Series B prep, Phase II design, regulatory filings, partnership due diligence Deliverables: 20-30 page report, presentation deck, 60-minute strategy debrief Timeline: 2 weeks | Investment: From £4,950
Competitive Intelligence Reports
For Specific Milestones & Decisions
Get a focused competitive landscape report in 2 weeks covering your key competitors, their strategies, and positioning recommendations. Perfect for: Series B prep, Phase II design, regulatory filings, partnership due diligence Deliverables: 20-30 page report, presentation deck, 60-minute strategy debrief Timeline: 2 weeks | Investment: From £4,950
Competitive Intelligence Reports
For Specific Milestones & Decisions
Get a focused competitive landscape report in 2 weeks covering your key competitors, their strategies, and positioning recommendations. Perfect for: Series B prep, Phase II design, regulatory filings, partnership due diligence Deliverables: 20-30 page report, presentation deck, 60-minute strategy debrief Timeline: 2 weeks | Investment: From £4,950
Monthly Intelligence Subscription
Receive regular intelligence briefings, real-time alerts on competitor moves, regulatory updates, and strategic analysis—without enterprise platform costs.
Perfect for: Programs with 3+ active competitors, ongoing trial planning, continuous market monitoring
Deliverables: Monthly reports, weekly alerts, quarterly strategy calls
Investment: Custom pricing based on scope
Monthly Intelligence Subscription
Receive regular intelligence briefings, real-time alerts on competitor moves, regulatory updates, and strategic analysis—without enterprise platform costs.
Perfect for: Programs with 3+ active competitors, ongoing trial planning, continuous market monitoring
Deliverables: Monthly reports, weekly alerts, quarterly strategy calls
Investment: Custom pricing based on scope
Monthly Intelligence Subscription
Receive regular intelligence briefings, real-time alerts on competitor moves, regulatory updates, and strategic analysis—without enterprise platform costs.
Perfect for: Programs with 3+ active competitors, ongoing trial planning, continuous market monitoring
Deliverables: Monthly reports, weekly alerts, quarterly strategy calls
Investment: Custom pricing based on scope
AI in Safety Compliance Report
Our flagship report analyzing how pharmaceutical companies are positioning AI in drug safety and compliance—including competitive strategies, regulatory approaches, and market opportunities. 50+ page comprehensive analysis | Immediately available
AI in Safety Compliance Report
Our flagship report analyzing how pharmaceutical companies are positioning AI in drug safety and compliance—including competitive strategies, regulatory approaches, and market opportunities. 50+ page comprehensive analysis | Immediately available
AI in Safety Compliance Report
Our flagship report analyzing how pharmaceutical companies are positioning AI in drug safety and compliance—including competitive strategies, regulatory approaches, and market opportunities. 50+ page comprehensive analysis | Immediately available
OUR APPROACH
Why LucidBio Intelligence?
Analyst-Driven Intelligence vs. Enterprise Platforms
Focused on Early-Stage Biotech
We understand your challenges: limited budgets, fast timelines, and the need to demonstrate strategic differentiation to investors and partners. Unlike enterprise platforms built for big pharma, our services are designed for lean biotech teams.
Analyst-Driven, Not Data Dumps
Every report and briefing is created by regulatory and clinical development specialists—not automated dashboards or AI-generated content. You get human expertise and strategic recommendations, not just database access.
OUR APPROACH
Why LucidBio Intelligence?
Analyst-Driven Intelligence vs. Enterprise Platforms
Focused on Early-Stage Biotech
We understand your challenges: limited budgets, fast timelines, and the need to demonstrate strategic differentiation to investors and partners. Unlike enterprise platforms built for big pharma, our services are designed for lean biotech teams.
Analyst-Driven, Not Data Dumps
Every report and briefing is created by regulatory and clinical development specialists—not automated dashboards or AI-generated content. You get human expertise and strategic recommendations, not just database access.
OUR APPROACH
Optimize Interaction with Advanced AI
Analyst-Driven Intelligence vs. Enterprise Platforms
Focused on Early-Stage Biotech
We understand your challenges: limited budgets, fast timelines, and the need to demonstrate strategic differentiation to investors and partners. Unlike enterprise platforms built for big pharma, our services are designed for lean biotech teams.
Analyst-Driven, Not Data Dumps
Every report and briefing is created by regulatory and clinical development specialists—not automated dashboards or AI-generated content. You get human expertise and strategic recommendations, not just database access.
Fast Turnaround
2-week delivery for one-time reports. Real-time alerts for subscription clients. No 6-month enterprise procurement cycles. We move at biotech speed.
Actionable Recommendations
We don't just tell you what competitors are doing—we tell you what it means for your strategy and what you should do about it.
Strategic intelligence you can actually use.
See Our Work
Case Study
Case Study: How a Seed-Stage Oncology Startup
Overview: A European biotech company pursuing PRIME designation for a novel oncology asset faced ambiguity in how best to position their Phase II trial for regulatory endorsement.By refining the study’s primary endpoints, inclusion criteria, and statistical analysis approach, the regulatory strategy was aligned with scientific precedent, resulting in a streamlined clinical–regulatory model that eliminated misaligned iterations, reduced time and investment, and enabled EMA scientific advice with no major objections to the client's fast track strategy.
See Our Work
Case Study
Case Study: How a Seed-Stage Oncology Startup
Overview: A European biotech company pursuing PRIME designation for a novel oncology asset faced ambiguity in how best to position their Phase II trial for regulatory endorsement.By refining the study’s primary endpoints, inclusion criteria, and statistical analysis approach, the regulatory strategy was aligned with scientific precedent, resulting in a streamlined clinical–regulatory model that eliminated misaligned iterations, reduced time and investment, and enabled EMA scientific advice with no major objections to the client's fast track strategy.
See Our Work
Case Study
Case Study: How a Seed-Stage Oncology Startup
Overview: A European biotech company pursuing PRIME designation for a novel oncology asset faced ambiguity in how best to position their Phase II trial for regulatory endorsement.By refining the study’s primary endpoints, inclusion criteria, and statistical analysis approach, the regulatory strategy was aligned with scientific precedent, resulting in a streamlined clinical–regulatory model that eliminated misaligned iterations, reduced time and investment, and enabled EMA scientific advice with no major objections to the client's fast track strategy.
See our comprehensive competitive intelligence approach with our featured report analyzing 12+ pharmaceutical companies' AI positioning strategies. Executive summary available free.
See our comprehensive competitive intelligence approach with our featured report analyzing 12+ pharmaceutical companies' AI positioning strategies. Executive summary available free.
See our comprehensive competitive intelligence approach with our featured report analyzing 12+ pharmaceutical companies' AI positioning strategies. Executive summary available free.
Download: AI in Safety Compliance Report
Download: AI in Safety Compliance Report
Download: AI in Safety Compliance Report
Built for Strategy Teams Working Under Pressure
AI in life sciences isn’t just disruptive — it’s destabilizing. We help you make sense of complex vendor claims, shifting regulatory signals, and emerging risks before they reach your doorstep.
Strategic tools built for regulatory and commercial alignment
Real-world insights — not generic dashboards
Frameworks that support cross-functional decisions
CI mapped to live market signals and risk posture
Deliverables built for use in internal strategy and compliance workflows
Flexible access models across stages, teams, and reporting depth
Built for Strategy Teams Working Under Pressure
AI in life sciences isn’t just disruptive — it’s destabilizing. We help you make sense of complex vendor claims, shifting regulatory signals, and emerging risks before they reach your doorstep.
Strategic tools built for regulatory and commercial alignment
Real-world insights — not generic dashboards
Frameworks that support cross-functional decisions
CI mapped to live market signals and risk posture
Deliverables built for use in internal strategy and compliance workflows
Flexible access models across stages, teams, and reporting depth
Built for Strategy Teams Working Under Pressure
AI in life sciences isn’t just disruptive — it’s destabilizing. We help you make sense of complex vendor claims, shifting regulatory signals, and emerging risks before they reach your doorstep.
Strategic tools built for regulatory and commercial alignment
Real-world insights — not generic dashboards
Frameworks that support cross-functional decisions
CI mapped to live market signals and risk posture
Deliverables built for use in internal strategy and compliance workflows
Flexible access models across stages, teams, and reporting depth
Start With a Free Competitive Brief
Not ready to commit? We'll send you a 1-page competitive intelligence brief specific to your indication or therapeutic area—no cost, no obligation.
What you'll get
What you'll get
What you'll get
Overview of 3-5 key competitors in your space
Recent strategic moves or milestones
2-3 preliminary insights relevant to your program
Zero cost, zero pressure
How is this different from enterprise platforms like AlphaSense or Cortellis?
Enterprise platforms provide self-service database access—you search and analyze yourself. We provide analyst-driven strategic intelligence—human experts who deliver insights and recommendations specific to your needs. Think of us as your fractional CI team, not a software subscription.
What’s shifting in the landscape — and why should I care now?
Because timing matters. We track not just competitor actions, but the strategic meaning behind them.
How do you gather competitive intelligence?
We analyze publicly available sources including ClinicalTrials.gov, regulatory databases, scientific publications, company press releases, investor presentations, and conference proceedings. All work is conducted ethically and legally. We never use corporate espionage or questionable methods.
Can I use these reports in investor materials?
Yes. The reports are yours to use as you see fit—in pitch decks, board presentations, or strategic planning documents. We can also format deliverables to match your investor deck style upon request.
What if my competitors are private companies with limited information?
We specialize in piecing together intelligence from fragmentary sources. Even private biotechs leave digital footprints through trial registries, publications, patents, job postings, and conference presentations. This is where analyst expertise matters—connecting the dots that platforms miss.
How long does it take to get a competitive intelligence report?
One-time reports: 2 weeks from kickoff to final delivery, including a 60-minute strategy debrief call. Free competitive briefs: 3-5 business days. Monthly subscriptions: Initial setup takes 1-2 weeks, then you receive ongoing briefings on your chosen schedule (weekly, bi-weekly, or monthly). We prioritize speed without sacrificing quality—perfect for biotech teams working against tight timelines.
What if I'm not sure which service I need?
Start with our free 1-page competitive brief. This gives you a taste of our analysis style and helps us understand your specific needs. Based on that initial brief, we can recommend whether a one-time report, monthly subscription, or custom project makes the most sense for your situation. No pressure, no obligation—we'd rather recommend the right fit than oversell.
Do you work with companies outside the UK?
Yes, we have operations in UK & US. We work with biotech companies globally—UK, EU, US, Canada, and beyond. Our intelligence coverage is international (we track FDA, EMA, PMDA, and other regulatory bodies), and we deliver reports remotely via video calls and digital documents. Time zone differences are never an issue—we schedule debriefs at times that work for your team.
How is this different from enterprise platforms like AlphaSense or Cortellis?
Enterprise platforms provide self-service database access—you search and analyze yourself. We provide analyst-driven strategic intelligence—human experts who deliver insights and recommendations specific to your needs. Think of us as your fractional CI team, not a software subscription.
What’s shifting in the landscape — and why should I care now?
Because timing matters. We track not just competitor actions, but the strategic meaning behind them.
How do you gather competitive intelligence?
We analyze publicly available sources including ClinicalTrials.gov, regulatory databases, scientific publications, company press releases, investor presentations, and conference proceedings. All work is conducted ethically and legally. We never use corporate espionage or questionable methods.
Can I use these reports in investor materials?
Yes. The reports are yours to use as you see fit—in pitch decks, board presentations, or strategic planning documents. We can also format deliverables to match your investor deck style upon request.
What if my competitors are private companies with limited information?
We specialize in piecing together intelligence from fragmentary sources. Even private biotechs leave digital footprints through trial registries, publications, patents, job postings, and conference presentations. This is where analyst expertise matters—connecting the dots that platforms miss.
How long does it take to get a competitive intelligence report?
One-time reports: 2 weeks from kickoff to final delivery, including a 60-minute strategy debrief call. Free competitive briefs: 3-5 business days. Monthly subscriptions: Initial setup takes 1-2 weeks, then you receive ongoing briefings on your chosen schedule (weekly, bi-weekly, or monthly). We prioritize speed without sacrificing quality—perfect for biotech teams working against tight timelines.
What if I'm not sure which service I need?
Start with our free 1-page competitive brief. This gives you a taste of our analysis style and helps us understand your specific needs. Based on that initial brief, we can recommend whether a one-time report, monthly subscription, or custom project makes the most sense for your situation. No pressure, no obligation—we'd rather recommend the right fit than oversell.
Do you work with companies outside the UK?
Yes, we have operations in UK & US. We work with biotech companies globally—UK, EU, US, Canada, and beyond. Our intelligence coverage is international (we track FDA, EMA, PMDA, and other regulatory bodies), and we deliver reports remotely via video calls and digital documents. Time zone differences are never an issue—we schedule debriefs at times that work for your team.
How is this different from enterprise platforms like AlphaSense or Cortellis?
Enterprise platforms provide self-service database access—you search and analyze yourself. We provide analyst-driven strategic intelligence—human experts who deliver insights and recommendations specific to your needs. Think of us as your fractional CI team, not a software subscription.
What’s shifting in the landscape — and why should I care now?
Because timing matters. We track not just competitor actions, but the strategic meaning behind them.
How do you gather competitive intelligence?
We analyze publicly available sources including ClinicalTrials.gov, regulatory databases, scientific publications, company press releases, investor presentations, and conference proceedings. All work is conducted ethically and legally. We never use corporate espionage or questionable methods.
Can I use these reports in investor materials?
Yes. The reports are yours to use as you see fit—in pitch decks, board presentations, or strategic planning documents. We can also format deliverables to match your investor deck style upon request.
What if my competitors are private companies with limited information?
We specialize in piecing together intelligence from fragmentary sources. Even private biotechs leave digital footprints through trial registries, publications, patents, job postings, and conference presentations. This is where analyst expertise matters—connecting the dots that platforms miss.
How long does it take to get a competitive intelligence report?
One-time reports: 2 weeks from kickoff to final delivery, including a 60-minute strategy debrief call. Free competitive briefs: 3-5 business days. Monthly subscriptions: Initial setup takes 1-2 weeks, then you receive ongoing briefings on your chosen schedule (weekly, bi-weekly, or monthly). We prioritize speed without sacrificing quality—perfect for biotech teams working against tight timelines.
What if I'm not sure which service I need?
Start with our free 1-page competitive brief. This gives you a taste of our analysis style and helps us understand your specific needs. Based on that initial brief, we can recommend whether a one-time report, monthly subscription, or custom project makes the most sense for your situation. No pressure, no obligation—we'd rather recommend the right fit than oversell.
Do you work with companies outside the UK?
Yes, we have operations in UK & US. We work with biotech companies globally—UK, EU, US, Canada, and beyond. Our intelligence coverage is international (we track FDA, EMA, PMDA, and other regulatory bodies), and we deliver reports remotely via video calls and digital documents. Time zone differences are never an issue—we schedule debriefs at times that work for your team.
FAQs
Clarity You Can Act On — Not Just Read
FAQs
Clarity You Can Act On — Not Just Read
FAQs
FAQs
Clarity You Can Act On — Not Just Read
Why Teams Turn to LucidBio Intelligence
When AI is pushed as a one-size-fits-all solution, strategic intelligence becomes essential.
We help life sciences teams examine the real impact — where AI creates value, where it breaks systems, and how to move forward without regret.
Used by global pharma teams navigating AI, compliance, and policy pressure.
4.7/5 on Trustp
Why Teams Turn to LucidBio Intelligence
When AI is pushed as a one-size-fits-all solution, strategic intelligence becomes essential.
We help life sciences teams examine the real impact — where AI creates value, where it breaks systems, and how to move forward without regret.
Used by global pharma teams navigating AI, compliance, and policy pressure.
4.7/5
Why Teams Turn to LucidBio Intelligence
When AI is pushed as a one-size-fits-all solution, strategic intelligence becomes essential.
We help life sciences teams examine the real impact — where AI creates value, where it breaks systems, and how to move forward without regret.
Used by global pharma teams navigating AI, compliance, and policy pressure.
4.7/5 on Trustp
Blog Insight
“Where AI Meets Risk, Policy, and Compliance — We Map the Impact”
Blog Insight
Revolutionizing Strategic Intelligence
Blog Insight
“Where AI Meets Risk, Policy, and Compliance — We Map the Impact”
Get Started
Ready To Gain An Edge On A Volatile Life Science Landscape
AI in Safety Compliance Competitive Intelligence Report
Get Started
Ready To Gain An Edge On A Volatile Life Science Landscape
AI in Safety Compliance Competitive Intelligence Report
Get Started
Ready To Gain An Edge On A Volatile Life Science Landscape
AI in Safety Compliance Competitive Intelligence Report